Your browser doesn't support javascript.
loading
Alkyl-Modified Oligonucleotides as Intercalating Vehicles for Doxorubicin Uptake via Albumin Binding.
Purdie, Laura; Alexander, Cameron; Spain, Sebastian G; Magnusson, Johannes P.
Affiliation
  • Purdie L; School of Pharmacy, University of Nottingham , University Park, Nottingham NG7 2RD, U.K.
  • Alexander C; School of Pharmacy, University of Nottingham , University Park, Nottingham NG7 2RD, U.K.
  • Spain SG; Department of Chemistry, University of Sheffield , Sheffield S3 7HF, U.K.
  • Magnusson JP; School of Pharmacy, University of Nottingham , University Park, Nottingham NG7 2RD, U.K.
Mol Pharm ; 15(2): 437-446, 2018 02 05.
Article in En | MEDLINE | ID: mdl-29265823
ABSTRACT
DNA-based drug delivery vehicles have displayed promise for the delivery of intercalating drugs. Here, we demonstrate that oligonucleotides modified with an alkyl chain can bind to human serum albumin, mimicking the natural binding of fatty acids. These alkyl-DNA-albumin complexes display excellent serum stability and are capable of strongly binding doxorubicin. Complexes are internalized by cells in vitro, trafficking to the mitochondria, and are capable of delivering doxorubicin with excellent efficiency resulting in cell death. However, the cellular localization of the delivered doxorubicin, and ultimately the complex efficacy, is dependent on the nature of the linker between the alkyl group and the oligonucleotide.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Oligonucleotides / Pharmaceutical Vehicles / Doxorubicin / Intercalating Agents / Antibiotics, Antineoplastic Limits: Humans Language: En Year: 2018 Type: Article

Full text: 1 Database: MEDLINE Main subject: Oligonucleotides / Pharmaceutical Vehicles / Doxorubicin / Intercalating Agents / Antibiotics, Antineoplastic Limits: Humans Language: En Year: 2018 Type: Article